Pharmacokinetics-based clinical management of acquired von willebrand syndrome: A case report

Candice M. Baldeo, Candido E Rivera, Han W Tun, Prakash Vishnu

Research output: Contribution to journalArticle

Abstract

von Willebrand disease (VWD) is a common bleeding disorder caused by defective or low levels of von Willebrand factor (VWF). Although most cases of VWD are caused by genetic mutations, some are acquired due to various disease states. In managing VWD, the aim is to normalize plasma levels of both VWF and factor VIII (FVIII), as this aids in hemostasis. Desmopressin usually corrects VWF level in type 1 VWD by inducing the release of endogenous VWF. In cases where desmopressin is ineffective or cannot be used, transfusion of virally inactivated, plasma-derived VWF/FVIII concentrate or infusion of recombinant VWF (Vonvendi) is indicated. Treatment of acquired von Willebrand syndrome (AVWS) aims to control the underlying disease while regulating life-threatening hemorrhages with infusions of VWF/FVIII concentrate. Wide intrasubject variability in VWF and FVIII levels, particularly in AVWS, necessitates verification of response to treatment by frequent monitoring of the plasmatic VWF level. Clinical pharmacokinetics of VWF may facilitate calculation of the necessary loading and maintenance doses of VWF/FVIII concentrate in the management of AVWS patients undergoing surgery, thereby avoiding unnecessary infusion of coagulation factor concentrate.

Original languageEnglish (US)
Pages (from-to)9-13
Number of pages5
JournalJournal of Blood Medicine
Volume9
DOIs
StatePublished - Jan 19 2018

Fingerprint

von Willebrand Factor
Pharmacokinetics
von Willebrand Diseases
Deamino Arginine Vasopressin
Type 1 von Willebrand Disease
Hemorrhage
Blood Coagulation Factors
Hemostasis
factor VIII, von Willebrand factor drug combination
Mutation
Therapeutics

Keywords

  • Acquired von willebrand syndrome
  • Bleeding disorder
  • Pharmacokinetics
  • Surgical hemostasis

ASJC Scopus subject areas

  • Hematology

Cite this

Pharmacokinetics-based clinical management of acquired von willebrand syndrome : A case report. / Baldeo, Candice M.; Rivera, Candido E; Tun, Han W; Vishnu, Prakash.

In: Journal of Blood Medicine, Vol. 9, 19.01.2018, p. 9-13.

Research output: Contribution to journalArticle

@article{2e70b9accabe4c18b925461c5a00ebae,
title = "Pharmacokinetics-based clinical management of acquired von willebrand syndrome: A case report",
abstract = "von Willebrand disease (VWD) is a common bleeding disorder caused by defective or low levels of von Willebrand factor (VWF). Although most cases of VWD are caused by genetic mutations, some are acquired due to various disease states. In managing VWD, the aim is to normalize plasma levels of both VWF and factor VIII (FVIII), as this aids in hemostasis. Desmopressin usually corrects VWF level in type 1 VWD by inducing the release of endogenous VWF. In cases where desmopressin is ineffective or cannot be used, transfusion of virally inactivated, plasma-derived VWF/FVIII concentrate or infusion of recombinant VWF (Vonvendi) is indicated. Treatment of acquired von Willebrand syndrome (AVWS) aims to control the underlying disease while regulating life-threatening hemorrhages with infusions of VWF/FVIII concentrate. Wide intrasubject variability in VWF and FVIII levels, particularly in AVWS, necessitates verification of response to treatment by frequent monitoring of the plasmatic VWF level. Clinical pharmacokinetics of VWF may facilitate calculation of the necessary loading and maintenance doses of VWF/FVIII concentrate in the management of AVWS patients undergoing surgery, thereby avoiding unnecessary infusion of coagulation factor concentrate.",
keywords = "Acquired von willebrand syndrome, Bleeding disorder, Pharmacokinetics, Surgical hemostasis",
author = "Baldeo, {Candice M.} and Rivera, {Candido E} and Tun, {Han W} and Prakash Vishnu",
year = "2018",
month = "1",
day = "19",
doi = "10.2147/JBM.S152663",
language = "English (US)",
volume = "9",
pages = "9--13",
journal = "Journal of Blood Medicine",
issn = "1179-2736",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Pharmacokinetics-based clinical management of acquired von willebrand syndrome

T2 - A case report

AU - Baldeo, Candice M.

AU - Rivera, Candido E

AU - Tun, Han W

AU - Vishnu, Prakash

PY - 2018/1/19

Y1 - 2018/1/19

N2 - von Willebrand disease (VWD) is a common bleeding disorder caused by defective or low levels of von Willebrand factor (VWF). Although most cases of VWD are caused by genetic mutations, some are acquired due to various disease states. In managing VWD, the aim is to normalize plasma levels of both VWF and factor VIII (FVIII), as this aids in hemostasis. Desmopressin usually corrects VWF level in type 1 VWD by inducing the release of endogenous VWF. In cases where desmopressin is ineffective or cannot be used, transfusion of virally inactivated, plasma-derived VWF/FVIII concentrate or infusion of recombinant VWF (Vonvendi) is indicated. Treatment of acquired von Willebrand syndrome (AVWS) aims to control the underlying disease while regulating life-threatening hemorrhages with infusions of VWF/FVIII concentrate. Wide intrasubject variability in VWF and FVIII levels, particularly in AVWS, necessitates verification of response to treatment by frequent monitoring of the plasmatic VWF level. Clinical pharmacokinetics of VWF may facilitate calculation of the necessary loading and maintenance doses of VWF/FVIII concentrate in the management of AVWS patients undergoing surgery, thereby avoiding unnecessary infusion of coagulation factor concentrate.

AB - von Willebrand disease (VWD) is a common bleeding disorder caused by defective or low levels of von Willebrand factor (VWF). Although most cases of VWD are caused by genetic mutations, some are acquired due to various disease states. In managing VWD, the aim is to normalize plasma levels of both VWF and factor VIII (FVIII), as this aids in hemostasis. Desmopressin usually corrects VWF level in type 1 VWD by inducing the release of endogenous VWF. In cases where desmopressin is ineffective or cannot be used, transfusion of virally inactivated, plasma-derived VWF/FVIII concentrate or infusion of recombinant VWF (Vonvendi) is indicated. Treatment of acquired von Willebrand syndrome (AVWS) aims to control the underlying disease while regulating life-threatening hemorrhages with infusions of VWF/FVIII concentrate. Wide intrasubject variability in VWF and FVIII levels, particularly in AVWS, necessitates verification of response to treatment by frequent monitoring of the plasmatic VWF level. Clinical pharmacokinetics of VWF may facilitate calculation of the necessary loading and maintenance doses of VWF/FVIII concentrate in the management of AVWS patients undergoing surgery, thereby avoiding unnecessary infusion of coagulation factor concentrate.

KW - Acquired von willebrand syndrome

KW - Bleeding disorder

KW - Pharmacokinetics

KW - Surgical hemostasis

UR - http://www.scopus.com/inward/record.url?scp=85042451196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042451196&partnerID=8YFLogxK

U2 - 10.2147/JBM.S152663

DO - 10.2147/JBM.S152663

M3 - Article

AN - SCOPUS:85042451196

VL - 9

SP - 9

EP - 13

JO - Journal of Blood Medicine

JF - Journal of Blood Medicine

SN - 1179-2736

ER -